BriaCell Therapeutics Corp. (BCTX)
$3.71-4.13%Close
SELLRECOVERY · day 49
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7M
- Beta
- 1.52
- P/E (TTM)
- -0.31
- Short % float
- 46.78%
- Days to cover
- 3.9
- SI change
- -1.7%
- 1W
- -7.71%
- 1M
- +4.21%
- vs SPY 1W
- -7.57%
- vs SPY 1M
- +1.71%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 16
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-88.7%
REV YoY-
ROE-147.9%
EPS YoY-
ROA-113.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.31
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.13
P/FCF-
EV/EBITDA-0.81
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.07
ND/EBITDA-
BETA1.52
Company news
FAQ
- What is LOPJLB’s current signal on BCTX?
- LOPJLB’s latest quantitative signal on BriaCell Therapeutics Corp. (BCTX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is BCTX in?
- BriaCell Therapeutics Corp. (BCTX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does BriaCell Therapeutics Corp. (BCTX) do?
- BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Be…